Results 91 to 100 of about 1,591,450 (336)

IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment

open access: yesFrontiers in Oncology, 2021
Metastatic breast cancer remains a largely incurable and fatal disease with liver involvement bearing the worst prognosis. The danger is compounded by a subset of disseminated tumor cells that may lie dormant for years to decades before re-emerging as ...
Amanda M. Clark   +10 more
doaj   +1 more source

Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer [PDF]

open access: yes, 2017
Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not associated with the vasculature, of patients with early breast cancer express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), receptor activator ...
Borzone, Francisco Raúl   +12 more
core   +2 more sources

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

Metastatic Breast Cancer to the Common Bile Duct Presenting as Obstructive Jaundice

open access: yesCase Reports in Gastroenterology, 2015
Metastatic breast cancer is typically identified in the bones, lymph nodes, lungs and liver. Rarely does metastatic breast cancer involve the common bile duct (CBD) without direct extension from liver metastasis into the CBD. We present a woman diagnosed
Justin Cochrane, Greg Schlepp
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

open access: yes, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar   +69 more
core   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy

open access: yesCase Reports in Oncology, 2019
Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeutic ...
Toko Kumeta   +4 more
doaj   +1 more source

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

open access: yesJournal of Experimental & Clinical Cancer Research, 2021
Breast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and bone.
Cenzhu Wang   +5 more
doaj   +1 more source

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. [PDF]

open access: yes, 2017
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Michael Pimienta   +4 more
core   +2 more sources

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

open access: yesNew England Journal of Medicine, 2019
BACKGROUND Standard chemotherapy is associated with low response rates and short progression‐free survival among patients with pretreated metastatic triple‐negative breast cancer.
A. Bardia   +18 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy